Recent studies have highlighted that systemic lupus erythematosus (SLE) is characterized by different types of symptoms: type 1 symptoms related to inflammation and disease activity and type 2 symptoms such as fatigue, anxiety-depression, and pain. Our aim was to investigate the relation between type 1 and type 2 symptoms, and their impact on health-related quality of life (HRQoL) in SLE.
Methods
A literature review was conducted about disease activity/type1 and type 2 symptoms. Articles in English published after 2000 were located on Medline via Pubmed. The articles chosen evaluated at least one type 2 symptom or HRQoL using a validated scale in adult patients.
Results
Overall, 182 articles were analyzed and 115 were retained including 21 randomized, controlled trials and corresponding to 36 831 patients. We found that in SLE, inflammatory activity/type 1 symptoms were mostly uncorrelated with type 2 symptoms and/or HRQoL. Several studies even showing an inverse relationship. No or weak correlation was observed in 85, 3% (92, 6%), 76, 7% (74, 4%) and 37, 5% (73, 1%) of studies (patients) for fatigue, anxiety-depression, and pain, respectively. For HRQoL, no or weak correlation was observed in 77, 5% of studies (88% of patients).
Conclusion
Type 2 symptoms are poorly correlated with inflammatory activity/type 1 symptoms in SLE. Possible explanations and implications for clinical care and therapeutic evaluation are discussed.
DaviesKDuresENgWF. Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research. Nat Rev Rheumatol2021; 17(11): 651–664.
2.
PisetskyDSClowseMEBCriscione-SchreiberLG, et al.A novel system to categorize the symptoms of systemic lupus erythematosus. Arthritis Care Res2019; 71(6): 735–741.
3.
AhnGERamsey-GoldmanR. Fatigue in systemic lupus erythematosus. Int J Clin Rheumtol2012; 7(2): 217–227.
4.
PalaginiLMoscaMTaniC, et al.Depression and systemic lupus erythematosus: a systematic review. Lupus2013; 22(5): 409–416.
5.
EnnsMWBernsteinCNKroekerK, et al.The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases. In: SoundyA (ed) PLoS One2018; 13(6): e0198975.
6.
IannuccelliCSpinelliFRGuzzoMP, et al.Fatigue and widespread pain in systemic lupus erythematosus and Sjögren’s syndrome: symptoms of infiammatory disease or associated fibromyalgia?Clin Exp Rheumatol2012; 30: 117–121.
7.
McelhoneKAbbottJTehLS. A review of health related quality of life in systemic lupus erythematosus. Lupus2006; 15(10): 633–643.
8.
NevilleCClarkeAEJosephL, et al.Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity. J Rheumatol2000; 27(3): 675–679.
9.
GolderVOoiJJYAntonyAS, et al.Discordance of patient and physician health status concerns in systemic lupus erythematosus. Lupus2018; 27(3): 501–506.
10.
MorrisGBerkMGaleckiP, et al.The neuro-immune pathophysiology of central and peripheral fatigue in systemic immune-inflammatory and neuro-immune diseases. Mol Neurobiol2016; 53(2): 1195–1219.
11.
BeurelEToupsMNemeroffCB. The bidirectional relationship of depression and inflammation: double trouble. Neuron2020; 107(2): 234–256.
12.
FalasinnuTDrenkardCBaoG, et al.The problem of pain in systemic lupus erythematosus: an explication of the role of biopsychosocial mechanisms. J Rheumatol2021; 48(8): 1279–1289.
13.
MoazzamiMStrandVSuJ, et al.Dual trajectories of fatigue and disease activity in an inception cohort of adults with systemic lupus erythematosus over 10 years. Lupus2021; 30(4): 578–586.
14.
Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for Fatigue. Measurement of fatigue in systemic lupus erythematosus: a systematic review. Arthritis Rheum2007; 57(8): 1348–1357.
15.
ArnaudLGavandPEVollR, et al.Predictors of fatigue and severe fatigue in a large international cohort of patients with systemic lupus erythematosus and a systematic review of the literature. Rheumatology2019; 58(6): 987–996.
16.
PetriMAMartinRSScheinbergMA, et al.Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod. Lupus2017; 26(1): 27–37.
17.
StrandVBerryPLinX, et al.Long-term impact of belimumab on health-related quality of life and fatigue in patients with systemic lupus erythematosus: six years of treatment. Arthritis Care Res2019; 71(6): 829–838.
18.
GomezAQiuVCederlundA, et al.Adverse health-related quality of life outcome despite adequate clinical response to treatment in systemic lupus erythematosus. Front Med2021; 8: 651249.
19.
ParodisISjöwallCJönsenA, et al.Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. Autoimmun Rev2017; 16(4): 343–351.
20.
KozoraEEllisonMCWestS. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American college of rheumatology SLE neuropsychological battery. Arthritis Rheum2006; 55(4): 628–635.
21.
LaiJSBeaumontJLOgaleS, et al.Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial. J Rheumatol2011; 38(4): 672–679.
22.
TayerWGNicassioPMWeismanMH, et al.Disease status predicts fatigue in systemic lupus erythematosus. J Rheumatol2001; 28(9): 1999–2007.
23.
WilliamsEMHyerJMViswanathanR, et al.Cytokine balance and behavioral intervention; findings from the Peer Approaches to Lupus Self-Management (PALS) project. Hum Immunol2017; 78(9): 574–581.
24.
BurgosPIAlarcónGSMcGwinG, et al.Disease activity and damage are not associated with increased levels of fatigue in systemic lupus erythematosus patients from a multiethnic cohort: LXVII. Arthritis Rheum2009; 61(9): 1179–1186.
25.
HeijkeRBjörkMFrodlundM, et al.Relationship between remission, disease activity and patient-reported outcome measures in patients with recent-onset systemic lupus erythematosus. Lupus2020; 29(6): 625–630.
26.
AzizoddinDRJollyMAroraS, et al.Longitudinal study of fatigue, stress, and depression: role of reduction in stress toward improvement in fatigue. Arthritis Care Res2020; 72(10): 1440–1448.
27.
ShiYLiMLiuL, et al.Relationship between disease activity, organ damage and health-related quality of life in patients with systemic lupus erythematosus: a systemic review and meta-analysis. Autoimmun Rev2021; 20(1): 102691.
28.
NichilattiLPFernandesJMMarquesCP. Physiopathology of pain in systemic erythematosus lupus. Lupus2020; 29(7): 721–726.
29.
AzizoddinDRGandhiNWeinbergS, et al.Fatigue in systemic lupus: the role of disease activity and its correlates. Lupus2019; 28(2): 163–173.
30.
ArnaudLMertzPAmouraZ, et al.Patterns of fatigue and association with disease activity and clinical manifestations in systemic lupus erythematosus. Rheumatology2021; 60(6): 2672–2677.
31.
SeguierJJouveEBobotM, et al.Paradoxical association between blood modular interferon signatures and quality of life in patients with systemic lupus erythematosus. Rheumatol Oxf Engl2020; 59(8): 1975–1983.
32.
DaviesKMirzaKTarnJ, et al.Fatigue in primary Sjögren’s syndrome (pSS) is associated with lower levels of proinflammatory cytokines: a validation study. Rheumatol Int2019; 39(11): 1867–1873.
33.
MeyerTStanskeBKochenMM, et al.Elevated serum levels of interleukin-10 and tumor necrosis factor α [corrected] are both associated with vital exhaustion in patients with cardiovascular risk factors. Psychosomatics2010; 51(3): 248–256.
34.
Sarzi-PuttiniPGiorgiVMarottoD, et al.Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol2020; 16(11): 645–660.
35.
FlugeØRekelandIGLienK, et al.B-lymphocyte depletion in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med2019; 170(9): 585–593.
36.
PostalMLapaATSinicatoNA, et al.Depressive symptoms are associated with tumor necrosis factor alpha in systemic lupus erythematosus. J Neuroinflammation2016; 13(1): 5.
37.
PaluckaAKBlanckJPBennettL, et al.Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci2005; 102(9): 3372–3377.
38.
ChicheLJourde-ChicheNCornecD. Should the biopsychosocial model be considered in systemic autoimmune diseases? Comment on the article by Posada et al. Arthritis Rheumatol2021; 73(4): 717–718.
39.
Howard TrippNTarnJNatasariA, et al.Fatigue in primary Sjögren’s syndrome is associated with lower levels of proinflammatory cytokines. RMD Open2016; 2(2): e000282.
40.
PosadaJValadkhanSBurgeD, et al.Improvement of severe fatigue following nuclease therapy in patients with primary Sjögren’s syndrome: a randomized clinical trial. Arthritis Rheumatol2021; 73(1): 143–150.
41.
Wagner-JaureggJ. Fever therapy: its rationale in diseases of the nervous system. Edinb Med J1936; 43(1): 1–12.
42.
AderRCohenNFeltenD. Psychoneuroimmunology: interactions between the nervous system and the immune system. Lancet1995; 345(8942): 99–103.
43.
DantzerR. Neuroimmune interactions: from the brain to the immune system and vice versa. Physiol Rev2018; 98(1): 477–504.
Snyder-MacklerNSanzJKohnJN, et al.Social status alters immune regulation and response to infection in macaques. Science2016; 354(6315): 1041–1045.
46.
ZhangXLeiBYuanY, et al.Brain control of humoral immune responses amenable to behavioural modulation. Nature2020; 581(7807): 204–208.
47.
AranowCAtish-FregosoYLesserM, et al.Transcutaneous auricular vagus nerve stimulation reduces pain and fatigue in patients with systemic lupus erythematosus: a randomised, double-blind, sham-controlled pilot trial. Ann Rheum Dis2021; 80(2): 203–208.
48.
GenoveseMCGaylisNBSikesD, et al.Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study. Lancet Rheumatol2020; 2(9): e527–e538.
49.
FangthamMKasturiSBannuruRR, et al.Non-pharmacologic therapies for systemic lupus erythematosus. Lupus2019; 28(6): 703–712.
50.
EudyAMRogersJLCorneliA, et al.Intermittent and persistent type 2 lupus: patient perspectives on two distinct patterns of type 2 SLE symptoms. Lupus Sci Med2022; 9(1): e000705.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
